Steering CAR T cells to distinguish friend from foe

Hillary G. Caruso, Amy B. Heimberger, Laurence J.N. Cooper*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

17 Scopus citations

Abstract

CD19-specific chimeric antigen receptor (CAR)+ T cells have demonstrated clinical efficacy and long-lasting remissions, concomitant with tolerable normal B-cell aplasia. However, many tumor-associated antigens (TAAs) are expressed on normal tissues, the destruction of which would lead to intolerable toxicity. Thus, there is a need to engineer CAR+ T cells with improved safety profiles to restrict toxicity against TAA-expressing normal tissues. Bioengineering approaches include: (i) targeting CAR+ T cells to the tumor site, (ii) limiting CAR+ T-cell persistence, and (iii) restricting CAR activation. We review and evaluate strategies to engineer CAR+ T cells to reduce the potential of on-target, off-tissue toxicity.

Original languageEnglish (US)
Article numbere1271857
JournalOncoImmunology
Volume8
Issue number10
DOIs
StatePublished - 2019
Externally publishedYes

Keywords

  • Bioengineering
  • chimeric antigen receptor
  • on-target toxicity
  • T cell

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Fingerprint

Dive into the research topics of 'Steering CAR T cells to distinguish friend from foe'. Together they form a unique fingerprint.

Cite this